A partial response to abatacept in a patient with steroid resistant focal segmental glomerulosclerosis

dc.authorid0000-0002-3582-5075
dc.contributor.authorSoyaltın, Eren
dc.contributor.authorKasap Demir, Belde
dc.contributor.authorAlparslan, Caner
dc.contributor.authorArslansoyu Çamlar, Seçil
dc.contributor.authorAlaygut, Demet
dc.contributor.authorYavaşcan, Önder
dc.contributor.authorMutlubaş, Fatma
dc.date.accessioned2020-08-28T09:10:01Z
dc.date.available2020-08-28T09:10:01Z
dc.date.issued2020
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.description.abstractBackground. Herein we present our experience with abatacept in a patient diagnosed with primary focal segmental glomerulosclerosis (FSGS) and resistant to steroid and other immunosuppressives. Case. A 17-year-old girl was diagnosed with idiopathic nephrotic syndrome (NS) at the age of 8 years. Kidney biopsy was performed when she did not respond to 6-weeks of steroid (2mg/kg) therapy followed by three doses of pulse methylprednisolone (PMP) and considered as steroid resistant NS. The biopsy revealed focal segmental glomerulosclerosis (FSGS) and cyclophosphamide was added to the steroid treatment but the patient had no response. The genetic analysis revealed G34G/A318A compound homozygous synonym aminoacid variation in NPHS2 gene, thus all immunosuppressive regimes were stopped and she was put on supportive treatment. Throughout this period, she had nephrotic range of proteinuria, however serum albumin levels were >3g/dl. At the end of two years, the patient had NS with severe edema and hypoalbuminemia. When the genetic analysis was interpreted again, it was found to be consistent with a polymorphism rather than a mutation. Following 3 doses of PMP, oral steroid treatment was resumed and cyclosporine (CsA) was added to the treatment at the fifth year of follow up. However, she was unresponsive to CsA at the end of the first year as well as mycophenolate mofetil used for 12 months and rituximab used for 6 months, respectively. Then abatacept was instituted and proteinuria decreased below 1 gr/day and serum albumin levels increased to 3 g/dl at the end of 6 doses. Serum albumin levels remained stable in the following 7 months. Conclusion. Partial remission including the decrease in proteinuria and increase in albumin levels achieved in our patient encourages the usage of abatacept in patients who do not respond to multiple immunosuppressive therapies.
dc.identifier.citationSoyaltın, E., Kasap Demir, B., Alparslan, C., Arslansoyu Çamlar, S., Alaygut, D., Yavaşcan, Ö. ... Mutlubaş, F. (2020). A partial response to abatacept in a patient with steroid resistant focal segmental glomerulosclerosis. Turkish Journal of Pediatrics, 62(4), 663-667. https://dx.doi.org/10.24953/turkjped.2020.04.018
dc.identifier.doi10.24953/turkjped.2020.04.018
dc.identifier.endpage667
dc.identifier.issn0041-4301
dc.identifier.issue4
dc.identifier.scopusqualityQ3
dc.identifier.startpage663
dc.identifier.urihttps://dx.doi.org/10.24953/turkjped.2020.04.018
dc.identifier.urihttps://hdl.handle.net/20.500.12511/5758
dc.identifier.volume62
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTurkish Journal of Pediatrics
dc.relation.ispartofTurkish Journal of Pediatricsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectFocal Segmental Glomerulosclerosis
dc.subjectAbatacept
dc.subjectNephrotic Syndrome
dc.titleA partial response to abatacept in a patient with steroid resistant focal segmental glomerulosclerosis
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Yavascan, Onder-2020.pdf
Boyut:
635.22 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: